Sarcoidosis–Lymphoma Syndrome
Sarcoidosis and lymphoma can sometimes resemble one another, and rarely may occur in the same person. Persistent or unusual lymph-node enlargement, unexplained fever, night sweats, weight loss or a change in the disease pattern requires medical review.
Diagnosis relies on the clinical picture, imaging and, when indicated, tissue examination. Do not assume that every new symptom is caused by sarcoidosis.
Research described in the source review
The association between sarcoidosis and lymphoma was first described by Brincker in a series of 46 patients (14). In that series, sarcoidosis–lymphoma syndrome was defined as a condition in which sarcoidosis appeared several years before lymphoma was diagnosed. Sarcoidosis was most often diagnosed after the age of 40, and the most common lymphoma type was Hodgkin lymphoma (HL). By contrast, Papanikolaou and Sharma found that non-Hodgkin lymphomas (NHL) were the most common. In their series, newly enlarged lymph nodes or new involvement of the spleen were the main signs revealing lymphoma. These patients were, on average, 10 years older when sarcoidosis was diagnosed than unselected patients in most series (96, 97). Brincker’s historical analysis reported a 5.5-fold higher risk of developing lymphoma in patients with sarcoidosis than in the general population (14). A single-centre study described in the review compared patients with sarcoidosis–lymphoma syndrome with unselected patients with sarcoidosis and found significant differences in initial or subsequent characteristics. In particular, blood levels of angiotensin-converting enzyme (ACE) were higher in the sarcoidosis–lymphoma syndrome group. The sarcoidosis-only group was more likely to have lung involvement, a restrictive ventilatory defect and a higher relapse rate (98).
Among the reported sarcoidosis–lymphoma syndrome cases, lymphoma most often occurred 2–8 years after sarcoidosis was diagnosed, particularly in patients with a chronic disease course (14). The CD4/CD8 lymphocyte ratio in bronchoalveolar lavage fluid (BALF) was also higher in patients with sarcoidosis–lymphoma syndrome than in unselected patients (98). For example, levels of B-cell activating factor (BAFF) are elevated in patients with sarcoidosis and correlate with ACE levels (99). Increased levels of cytokines that promote cell proliferation, such as BAFF for B lymphocytes, could be a possible explanation for clonal proliferation in patients with sarcoidosis compared with other autoimmune diseases (100).
https://www.frontiersin.org/articles/10.3389/fmed.2020.594118/full